Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-L2 prophylactic papillomavirus vaccine

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 1061-1069

  Seitz, Hanna ^a   Dantheny, Tatiana ^b,d   Burkart, Frank ^a   Ottonello, Simone ^c   Müller, Martin ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITÉ CATHOLIQUE DE LYON   (France)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

THIOREDOXIN L2 PAPILLOMAVIRUS VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; OXIDATION; OXIDATION STATE; PRIORITY JOURNAL; PROTEIN MULTIMERIZATION;

ANIMALS; BACTERIAL PROTEINS; CAPSID PROTEINS; DRUG CARRIERS; FEMALE; MICE; MICE, INBRED BALB C; OXIDATION-REDUCTION; PAPILLOMAVIRUS VACCINES; PROTEIN MULTIMERIZATION; THIOREDOXINS; VACCINES, SYNTHETIC;

EID: 84880487016     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00195-13     Document Type: Article

References (39)

1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group. 2009. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 10:321-322.
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79.
3. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527. (Pubitemid 36159887)
4. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350.
5. Gissmann L. 2009. HPV vaccines: preclinical development. Arch. Med. Res. 40:466-470.
6. Schiller JT, Lowy DR. 2010. Vaccines to prevent infections by oncoviruses. Annu. Rev. Microbiol. 64:23-41.
7. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. 2007. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693-1702. (Pubitemid 46783792)
8. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
9. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. 2000. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 5:557-567.
10. Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU. 2001. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291:324-334. (Pubitemid 34095188)
11. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. 1996. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to typespecific epitopes on HPV-6. Virology 224:477-486. (Pubitemid 26364495)
12. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27. (Pubitemid 38737395)
13. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB. 2007. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol. 81:11585-11592. (Pubitemid 47623790)
14. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. 2007. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358:266-272. (Pubitemid 46136425)
15. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Müller M, Ottonello S. 2009. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -38) peptide displayed on bacterial thioredoxin. Vaccine 27:1949-1956.
16. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RBS. 2007. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 81:13927-13931. (Pubitemid 350247886)
17. Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, Tommasino M, Ottonello S, Müller M. 2011. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology 409:348-359.
18. Campos SK, Ozbun MA. 2009. Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS One 4:e4463. doi:10.1371/journal.pone.0004463.
19. Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, Müller M, Gissmann L. 2009. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J. Virol. 83:7690-7705.
20. Thönes N, Herreiner A, Schädlich L, Piuko K, Müller M. 2008. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J. Virol. 82:5472-5485. (Pubitemid 351705254)
21. Bachmann MF, Zinkernagel RM. 1996. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today 17:553-558. (Pubitemid 26423419)
22. Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F. 2008. The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. Infect. Immun. 76:3817-3823.
23. Ellman GL. 1959. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:70-77.
24. Moretto N, Bolchi A, Rivetti C, Imbimbo BP, Villetti G, Pietrini V, Polonelli L, Del Signore S, Smith KM, Ferrante RJ, Ottonello S. 2007. Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J. Biol. Chem. 282:11436-11445. (Pubitemid 47100761)
25. Riddles PW, Blakeley RL, Zerner B. 1983. Reassessment of Ellman's reagent. Methods Enzymol. 91:49-60.
26. Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Müller M, Kellner M, Horer M, Michaelis U, Roden RB, Gissmann L, Kleinschmidt JA. 2012. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 7:e39741.
27. Nakao S, Mori S, Kondo K, Matsumoto K, Yoshikawa H, Kanda T. 2012. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. Virology 434:110-117.
28. Schellenbacher C, Roden R, Kirnbauer R. 2009. Chimeric L1-L2 viruslike particles as potential broad-spectrum human papillomavirus vaccines. J. Virol. 83:10085-10095.
29. Schmitt M, Pawlita M. 2009. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res. 37:e119. doi:10.1093/nar/gkp581.
30. Seitz H, Schmitt M, Böhmer G, Kopp-Schneider A, Müller M. 2013. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Int. J. Cancer 132:E139-E148. doi:10.1002/ijc.27831.
31. Tumban E, Peabody J, Peabody DS, Chackerian B. 2011. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 6:e23310. doi:10.1371/journal. pone.0023310.
32. Wu WH, Gersch E, Kwak K, Jagu S, Karanam B, Huh WK, Garcea RL, Roden RBS. 2011. Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One 6:e27141. doi:10.1371/journal.pone.0027141.
33. Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, Poo H. 2012. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine 30:3286-3294.
34. Buck CB, Thompson CD. 2007. Production of papillomavirus-based gene transfer vectors. Curr. Protoc. Cell Biol. Chapter 26:Unit 26.1. doi:10.1002/0471143030.cb2601s37.
35. Kreider JW, Cladel NM, Patrick SD, Welsh PA, DiAngelo SL, Bower JM, Christensen ND. 1995. High efficiency induction of papillomas in vivo using recombinant cottontail rabbit papillomavirus DNA. J. Virol. Methods 55:233-244.
36. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RB. 2008. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl. Acad. Sci. U. S. A. 105:5850-5855. (Pubitemid 351758461)
37. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RBS. 2009. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J. Natl. Cancer Inst. 101:782-792.
38. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. 1996. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380:548-550. (Pubitemid 26110646)
39. Holmgren A. 1989. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264:13963-13966. (Pubitemid 19214215)